Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 405 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Brain Scan-PET Clear all
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

NCT00857415
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 23, 2026, 1:41 AM EDT
Active, not recruiting Not applicable Interventional

PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

NCT01266096
View directory record Official record
Conditions
Newly Diagnosed or Recurrent Metastatic Melanoma Patients, Malignant Brain Tumors
Interventions
PET scan with 124I-cRGDY-PEG-dots
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

NCT06032026
View directory record Official record
Conditions
Tauopathies
Interventions
11C-HY-2-15 PET, brain MRI, Amyloid PET scan, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 23, 2026, 1:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Imaging of Serotonin Transporters in the Brain

NCT00059046
View directory record Official record
Conditions
Healthy, Serotonin Transporter
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

NCT02079766
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy
Interventions
florbetapir F 18, Flortaucipir F18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Male only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Phoenix, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

NCT03809351
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[F-18]AV-1451-PET
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional

MRI in High-Grade Glioma Patients Undergoing Chemoradiation

NCT05212272
View directory record Official record
Conditions
High Grade Glioma
Interventions
PET-MRI Brain Scan, Blood draw, Memory testing, Optional lumbar puncture for cerebrospinal fluid collection
Procedure · Diagnostic Test · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

NCT00670800
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 23, 2026, 1:41 AM EDT
Terminated Phase 2 Interventional Results available

Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD

NCT03638466
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Interventions
Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task, SPN-810, Placebo
Diagnostic Test · Behavioral · Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Lakeland, Florida • Maitland, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects

NCT01992380
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Newport Beach, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efavirenz and Ritonavir on Human Brain P-Glycoprotein

NCT01668147
View directory record Official record
Conditions
Drug Effects
Interventions
[11C] desmethyl-loperamide, Control - no pretreatment, Oral ritonavir, Oral efavirenz
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 23, 2026, 1:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study

NCT02488720
View directory record Official record
Conditions
Cognition Disorders
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
65 Years to 85 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting No phase listed Observational

Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.

NCT07758270
View directory record Official record
Conditions
Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Remibrutinib, Ocrelizumab (US)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.

NCT07115017
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[18F] FZTA
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Translation of a Novel Brain PET Insert for Simultaneous PET/MR

NCT04383808
View directory record Official record
Conditions
Brain Disease
Interventions
Injected radiotracer with PET Insert, Pre-injected group with PET insert
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

NCT03587649
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Healthy Volunteers
Interventions
[18F]MNI-1126
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

NCT02649985
View directory record Official record
Conditions
Multiple Sclerosis, Alzheimer's Disease
Interventions
[F-18]PBR06, [C-11]PBR28
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 1:41 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Dynamic Connectivity Under Metabolic Constraints

NCT04106882
View directory record Official record
Conditions
Insulin Resistance, Healthy, Diet Modification, Aging
Interventions
Ketones, Glucose
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 23, 2026, 1:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers

NCT03903549
View directory record Official record
Conditions
Parkinson Disease
Interventions
[18F]P17-059
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 23, 2026, 1:41 AM EDT
Recruiting Not applicable Interventional

Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)

NCT05769348
View directory record Official record
Conditions
Chronic Migraine
Interventions
HD-tDCS Active Protocol, HD-tDCS Sham Protocol
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 23, 2026, 1:41 AM EDT